DAWN FY 2024 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$131M

Gross Profit

$126M96.0% margin

Operating Income

-$217M-165.7% margin

Net Income

-$95M-72.8% margin

EPS (Diluted)

$-1.02

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$80M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$583M

Total Liabilities

$80M

Stockholders' Equity

$503M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$0	—
Gross Profit	$126M	-$383,000	+32967.4%
Operating Income	-$217M	-$206M	-5.4%
Net Income	-$95M	-$189M	+49.5%